Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respirato… Read more
Enanta Pharmaceuticals Inc (ENTA) - Total Liabilities
Latest total liabilities as of December 2025: $202.91 Million USD
Based on the latest financial reports, Enanta Pharmaceuticals Inc (ENTA) has total liabilities worth $202.91 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Enanta Pharmaceuticals Inc - Total Liabilities Trend (2011–2025)
This chart illustrates how Enanta Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Enanta Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Enanta Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SNT Motiv Co Ltd
KO:064960
|
Korea | ₩259.97 Billion |
|
F.I.L.A. - Fabbrica Italiana Lapis ed Affini S.p.A
F:3S0
|
Germany | €552.46 Million |
|
Synektik S.A.
WAR:SNT
|
Poland | zł347.02 Million |
|
Ningbo Ocean Shipping Co. Ltd. A
SHG:601022
|
China | CN¥2.56 Billion |
|
Qudian Inc
NYSE:QD
|
USA | $2.00 Billion |
|
Tianyang Hot Mel
SHG:603330
|
China | CN¥872.42 Million |
|
GuangDong Leary New Material Technology Co. Ltd. A
SHG:688683
|
China | CN¥652.65 Million |
|
Electrosteel Castings Limited
NSE:ELECTCAST
|
India | ₹40.16 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Enanta Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.44 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Enanta Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Enanta Pharmaceuticals Inc (2011–2025)
The table below shows the annual total liabilities of Enanta Pharmaceuticals Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $216.01 Million | -12.84% |
| 2024-09-30 | $247.84 Million | +0.94% |
| 2023-09-30 | $245.54 Million | +314.37% |
| 2022-09-30 | $59.26 Million | +43.02% |
| 2021-09-30 | $41.43 Million | +17.67% |
| 2020-09-30 | $35.21 Million | +28.80% |
| 2019-09-30 | $27.34 Million | +33.04% |
| 2018-09-30 | $20.55 Million | -17.68% |
| 2017-09-30 | $24.96 Million | +120.10% |
| 2016-09-30 | $11.34 Million | +15.07% |
| 2015-09-30 | $9.86 Million | +45.78% |
| 2014-09-30 | $6.76 Million | +3.94% |
| 2013-09-30 | $6.50 Million | -20.99% |
| 2012-09-30 | $8.23 Million | -94.79% |
| 2011-09-30 | $158.06 Million | -- |